Screener
BridgeBio Pharma BBIO Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31, 2026 / Weighted-average Estimated Useful Lives | March 31, 2026 / Amount | December 31, 2025 / Weighted-average Estimated Useful Lives | December 31, 2025 / Amount |
|---|---|---|---|---|
| Gross amount | 13.7 years | $39,400 | 13.7 years | $39,400 |
| Less accumulated amortization | (12,041) | (11,323) | ||
| Total | $27,359 | $28,077 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's intangibles (net)?
- BridgeBio Pharma (BBIO) reported intangibles (net) of $27.36M in Q1 2026.
- How has BridgeBio Pharma's intangibles (net) changed year-over-year?
- BridgeBio Pharma's intangibles (net) decreased by 1.6% year-over-year, from $27.8M to $27.36M.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about BridgeBio Pharma's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude